Rh Alloimmunization Timeframe and Prevention

Understanding the Sensitization Process

Fetal RhD antigens appear extremely early, with fetal red blood cells displaying D-antigens from as early as 6 weeks of gestation, making maternal sensitization physiologically possible even in very early pregnancy 1, 2
Primary immune response timing varies, with only 60% of Rh-negative volunteers developing detectable antibodies after experimental injection with Rh-positive red cells, suggesting variable individual immune responsiveness 3
A small volume of Rh-positive red blood cells, as little as 0.03-0.1 mL, can trigger primary alloimmunization in susceptible individuals 4, 3

Most sensitization occurs at delivery, with approximately 90% of fetomaternal hemorrhage and alloimmunization events occurring during delivery itself 3, 5
Antepartum exposure increases with gestational age, with fetal cells detected in maternal circulation in 7% of first trimester pregnancies, 16% in second trimester, and 29% in third trimester 3, 5

Antibodies may not be immediately detectable, with actual immunization rates likely higher than the observed 17% in untreated Rh-negative mothers because antibody levels may be insufficient to detect until the early anamnestic response in a second Rh-positive pregnancy 3
Post-exposure testing should occur at least 4 weeks after exposure to allow time for antibody development 4

RhIg must be administered within 72 hours of exposure for optimal effectiveness, suppressing the maternal immune response to Rh-positive red blood cells 1

Early pregnancy is not safe from sensitization, as fetal RBCs with D-antigen are present from 6 weeks onward 2
Silent sensitization can occur, with some women becoming sensitized without any identified precipitating event 3
Individual variation in sensitization is substantial, with 40% of exposed individuals never developing antibodies even with repeated exposures 3

Maternal sensitization occurs when fetal red blood cells bearing foreign antigens cross into the maternal circulation through fetomaternal hemorrhage. 6
Only about 60 % of Rh‑negative women develop detectable anti‑D antibodies after exposure to Rh‑positive red cells, indicating considerable individual variability in immune response. 6

Fetal red blood cells are detectable in maternal blood in approximately 7 % of first‑trimester, 16 % of second‑trimester, and 29 % of third‑trimester pregnancies. 6
Documented sources of fetomaternal hemorrhage include invasive obstetric procedures such as amniocentesis, chorionic villous sampling, external cephalic version, as well as spontaneous events like threatened abortion. 6

Prior to the implementation of RhIg prophylaxis programs, fetal mortality attributable to Rh‑mediated hemolytic disease was 120 per 100 000 live births in the United Kingdom. 6
Following the introduction of postpartum RhIg prophylaxis in 1969, fetal mortality fell dramatically to 1.5 per 100 000 live births by 1989. 6

The true rate of maternal immunization is likely higher than the observed 17 % in untreated Rh‑negative mothers because low‑level antibodies may remain undetectable until an anamnestic response occurs in a subsequent Rh‑positive pregnancy. 6